Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Novolin 70/30 Clear all
Completed Phase 3 Interventional

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

NCT00135941
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
insulin glargine, insulin glulisine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Oct 17, 2026, 2:11 PM EDT
Terminated Phase 3 Interventional

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

NCT01308437
View directory record Official record
Conditions
Type I Diabetes
Interventions
Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Tustin, California • Hialeah, Florida • Hollywood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

NCT02660242
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
G-Pen Mini™ (glucagon injection), Glucose Tabs, Basal Insulin Reduction
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 17, 2026, 2:11 PM EDT
Withdrawn Phase 4 Interventional

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

NCT01971047
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Regular Insulin, Humalog
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

NCT01474018
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
QR-bromocriptine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

NCT00858273
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Antioxidant supplement, Diabetes treatment, Regular Insulin
Dietary Supplement · Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 17, 2026, 2:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

NCT06090864
View directory record Official record
Conditions
Hodgkin Lymphoma, Relapse, Refractory
Interventions
Chemotherapy, Cell infusion
Drug · Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Not applicable Interventional Results available

Evaluation of an Ascensia Blood Glucose Meter and App System

NCT02568384
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Onyx BG Meter / App System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 4 Interventional

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

NCT00791895
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart 30
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Results available

Veterans Inpatient Insulin Study and Transition to Outpatient Therapy

NCT00821795
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH/Regular 70/30 mix, insulin aspart protamine/insulin aspart 70/30 mix
Drug
Lead sponsor
Dennis G. Karounos, M.D.
Federal
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

NCT00313001
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 4 Interventional

INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study

NCT00101751
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, dietary regimen
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Results available

Insulin Glargine "All to Target" Trial

NCT00384085
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glulisine, Insulin Glargine, Premixed Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 80 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2011 · Synced Oct 17, 2026, 2:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies

NCT00560469
View directory record Official record
Conditions
Adipocyte Differentiation, Insulin Resistance
Interventions
Administration of 70% deuterated water
Other
Lead sponsor
University of Vermont
Other
Eligibility
40 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 17, 2026, 2:11 PM EDT
Not listed Phase 2 Interventional

Exercise For Sub-acute Stroke Patients in Jamaica

NCT01392391
View directory record Official record
Conditions
Stroke
Interventions
Task Oriented Exercise Training, Stroke Care "Get with the Guidelines"
Procedure
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Early Phase 1 Interventional

Controlled Insulin Delivery: Combining Technology With Treatment

NCT01484457
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed-loop session
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

NCT00097877
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
71
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 4 Interventional Results available

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

NCT02455076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 1 Interventional

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes

NCT03624062
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MAS-1 adjuvanted Insulin B-chain
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

NCT01358435
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
30% Regular Insulin Human Neutral and 70%Isophane Insulin, Novolin 70/30
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 17, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

NCT00598793
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, insulin glargine, metformin, pioglitazone
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Concord, California • Los Angeles, California • Walnut Creek, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 17, 2026, 2:11 PM EDT